Either way, the practical implication is similar, and it is arguably the most consequential consideration for anyone planning future work: on the brain-access hypothesis, novel dual GLP-1/GIP agonists engineered specifically for brain entry would be more rational next candidates to test than repurposed diabetes drugs chosen for market availability
At FitFocus MD, we assess your progress regularly and make science-based recommendations for continued success
Carotenoids are the main source of vitamin A in the body and also possess antioxidant properties
Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats
On-going support Access expert guidance, answers, and continuous care100% online, whenever you need it
Bruising after semaglutide shots is a common concern for patients using this glucagon-like peptide-1 (GLP-1) receptor agonist for type 2 diabetes or chronic weight management